Myovant sciences ltd. (MYOV)
CashFlow / TTM
Mar'20Dec'19Sep'19Jun'19Mar'19Dec'18Sep'18Jun'18Mar'18Dec'17Sep'17Jun'17Mar'17Dec'16Sep'16Jun'16Mar'16
Cash flows from operating activities:
Net Loss

-289,000

-299,114

-284,147

-279,317

-273,551

-246,790

-217,934

-182,072

-143,255

-116,676

-82,982

-87,787

-83,440

-63,423

0

0

0

Adjustments to reconcile net loss to net cash used in operating activities:
Share-based compensation

40,251

39,111

24,110

20,904

18,696

17,103

15,602

13,626

11,583

10,179

8,896

8,297

8,717

8,215

0

0

0

Depreciation and amortization

1,765

1,376

973

703

438

374

330

284

243

219

164

111

61

9

0

0

0

Amortization of debt discount and issuance costs

1,486

2,192

2,243

2,132

2,084

1,650

1,598

1,169

662

0

0

0

-

-

-

-

0

Acquisition of in-process research and development

-

-

-

-

-

-

-

-

-

-

-

-

13,117

13,117

0

0

0

Changes in the fair value of the Takeda warrant liability

-

-

-

-

-

-

-

-

-

-

-

-

27,518

28,815

0

0

0

Foreign currency translation adjustment

-

-

-

-

-

-

-

-

-

0

0

-124

-

0

0

0

0

Other items

1,980

738

-301

-97

-1,235

0

0

0

-

-

-

-

-

-

-

-

-

Changes in operating assets and liabilities:
Prepaid expenses and other current assets

-1,925

-288

1,590

2,991

5,055

7,095

4,641

520

1,918

4,126

3,700

5,182

3,221

1,153

0

0

0

Deferred tax assets

-

-

-

-

-

-

-

-

-208

0

0

0

208

0

0

0

0

Income tax receivable

524

767

750

524

476

-160

-662

-750

-895

0

0

0

-

-

-

-

-

Other assets

10

50

627

-25

-76

1,113

1,063

-297

3,065

1,998

1,998

3,074

0

100

0

0

0

Accounts payable

-

-

0

5,037

-

-

7,005

1,781

1,249

1,542

984

3,186

3,329

549

0

0

0

Income tax payable

-

-

-

-

-

-

-

-

-

-

0

0

-

-

0

0

-

Interest payable

-1,077

-429

5

386

795

429

300

372

282

0

0

0

-

-

-

-

0

Accrued expenses

-24,554

-3,130

5,869

7,741

23,349

27,528

23,894

27,013

18,287

17,681

13,281

10,825

11,755

3,135

0

0

0

Operating lease liabilities

-882

0

0

0

-

-

-

-

-

-

-

-

-

-

-

-

-

Due to former majority shareholder

-121

-66

-307

-5,011

-1,839

-3,617

-153

3,207

-1,070

1,361

-2,304

1,826

4,009

3,301

0

0

0

Deferred rent

-

-

-

-

-

-

-

-

-

-

-

3

-

0

0

0

0

Deferred interest payable

-2,273

-773

4,763

3,383

2,018

668

560

407

255

0

0

0

-

-

-

-

0

Net Cash Provided by (Used in) Operating Activities

-221,200

-255,008

-250,307

-246,133

-224,088

-205,969

-174,775

-135,453

-117,255

-92,931

-68,889

-44,772

-18,215

-7,550

0

0

0

Cash flows from investing activities:
Purchases of property and equipment

1,099

1,342

1,378

1,178

1,236

947

837

711

604

973

1,124

1,057

967

369

0

0

0

Net cash used in investing activities

-3,935

-16,978

-28,538

-1,178

-1,236

-947

-837

-711

-604

-973

-1,124

-1,057

-967

-369

0

0

0

Cash flows from financing activities:
Cash proceeds from issuance of common shares in initial public offering, net of underwriting discount

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

0

Initial public offering costs paid

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

0

Proceeds from issuance of common shares, net of issuance costs paid

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

0

Proceeds from stock option exercises

942

1,196

1,148

1,538

1,300

791

490

112

36

0

0

0

-

-

-

-

0

Cash proceeds from debt financings, net of financing costs paid

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

0

Cash capital contribution from RSL

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

0

Settlement of former majority shareholder common shares subscribed

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

0

Due to RSL and RSI for amounts paid on behalf of the Company

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

0

Net cash provided by financing activities

145,926

172,873

256,323

331,546

273,899

261,646

200,597

125,608

45,645

30,455

199,272

200,020

200,020

200,241

0

0

0

Net change in cash, cash equivalents and restricted cash

-79,181

-99,156

-22,570

84,224

48,575

54,730

24,985

-10,556

-72,214

-63,449

129,259

154,191

180,838

192,322

0

0

0

Non-cash financing activities:
Deferred financing costs included in accrued expenses

-

0

0

0

-

0

0

0

-

-

-

-

-

-

-

-

-

Offering costs, unpaid included in accrued expenses

-

-

-

-

-

-

-

-

-

-

0

0

-

-

-

-

-

Deferred initial public offering costs, unpaid

-

-

-

-

-

-

-

-

-

-

-

-

-

0

0

0

-

Acquisition of in-process research and development

-

-

-

-

-

-

-

-

-

-

-

-

13,117

13,117

0

0

0

Warrants issued to Hercules

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

0

Supplemental disclosure of cash paid:
Income taxes

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

0

0

Interest

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

0

Public Equity Offering
Proceeds from issuance of common shares, net of issuance costs paid

134,458

134,458

134,236

209,141

74,391

0

0

0

-

-

-

-

-

-

-

-

-